|
WO2008066783A2
|
|
Therapeutic materials and methods
|
|
WO2008016633A2
|
|
Combination therapy
|
|
WO2007024745A2
|
|
Phosphorus-containing macrocycles
|
|
CA2472341A1
|
|
Phosphorus-containing compounds & uses thereof
|
|
US2003206891A1
|
|
Rapamycin-based biological regulation
|
|
US2002161240A1
|
|
Synthetic multimerizing agents
|
|
AU8150501A
|
|
Immunosuppressant target proteins
|
|
US2002048792A1
|
|
Methods and materials for regulated production of proteins
|
|
EP1240345A2
|
|
Methods for expression of genes in primates
|
|
US7067526B1
|
|
28-epirapalogs
|
|
AU7072500A
|
|
28-epirapalogs
|
|
US6479653B1
|
|
Compositions and method for regulation of transcription
|
|
WO0078951A1
|
|
Chimeric oca-b transcription factors
|
|
AU5618300A
|
|
Chimeric hsf transcription factors
|
|
US6506379B1
|
|
Intramuscular delivery of recombinant AAV
|
|
CA2343917A1
|
|
Materials and methods involving conditional retention domains
|
|
WO0023600A1
|
|
Materials and methods involving conditional aggregation domains
|
|
AU1121000A
|
|
Materials and methods involving conditional retention domains
|
|
WO9958700A1
|
|
Multiviral compositions and uses thereof
|
|
AU2213299A
|
|
Regulation of biological events using multimeric chimeric proteins
|
